Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High-dose Cytarabine and Mitoxantrone
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
High-dose Cytarabine and Mitoxantrone (HAM) is a chemotherapy regimen primarily used in the treatment of acute myeloid leukemia (AML). This combination therapy involves cytarabine, an antimetabolite that disrupts DNA synthesis, and mitoxantrone, a topoisomerase II inhibitor that intercalates into DNA, leading to DNA damage and subsequent cell death. The regimen is designed to induce remission, particularly in older patients with relapsed or refractory AML.
- Other names
- Cytarabine and Mitoxantrone
02
Targets
POLB (DNA polymerase beta)DNATOP2A (DNA topoisomerase II)POLA1 (DNA polymerase alpha)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on High-dose Cytarabine and Mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on High-dose Cytarabine and Mitoxantrone.